Gyre Therapeutics, Inc. has recently released its 10-K report, providing a detailed overview of its business operations and financial performance. The company, a subsidiary of GNI USA, Inc., focuses on developing and commercializing small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. Gyre's product portfolio includes ETUARY (Pirfenidone) for the treatment of idiopathic pulmonary fibrosis, with ongoing Phase 3 trials for pneumoconiosis, as well as F351 (Hydronidone) under Phase 3 trials for chronic hepatitis B-associated liver fibrosis.
In the 10-K report, Gyre Therapeutics, Inc. discussed its financial performance, reporting a net income of $9.9 million for the year ended December 31, 2025, with an accumulated deficit of $68.4 million. The company also highlighted its revenue streams, primarily generated through sales of pharmaceutical products such as ETUARY®, Etorel®, and Contiva® in the People's Republic of China (PRC). Additionally, the report detailed the company's operating expenses, including cost of revenue, selling and marketing expenses, and research and development costs.
Furthermore, the 10-K report outlined Gyre Therapeutics, Inc.'s strategic initiatives, including the development of its lead candidate, Hydronidone, for the treatment of liver fibrosis. The company reported positive results from Phase 3 trials, with Hydronidone meeting its primary endpoint and demonstrating statistically significant improvements in inflammation without fibrosis progression. Gyre also provided updates on its product pipeline, including ongoing clinical trials for F573 in patients with liver injury and liver failure, as well as the advancement of F230 for the treatment of pulmonary arterial hypertension and F528 for chronic obstructive pulmonary disease.
The report also addressed key corporate developments, such as the Merger Agreement with Cullgen and Merger Sub, intended to qualify as a tax-free reorganization under the Internal Revenue Code. Additionally, Gyre Therapeutics, Inc. highlighted its commercial portfolio, including the procurement of Etorel® through the National Centralized Drug Procurement program and the acquisition of avatrombopag maleate tablets for the treatment of thrombocytopenia associated with chronic liver disease and chronic immune thrombocytopenia.
As a result of these announcements, the company's shares have moved -0.26% on the market, and are now trading at a price of $7.68. If you want to know more, read the company's complete 10-K report here.
